LifeArc® is a medical research charity making life science life changing, transforming promising life science ideas into medical breakthroughs that change patients’ lives. We are self-funding and specialise in early-stage translation – advancing lab-based scientific discoveries to a point at which they can be developed into the next generation of diagnostics, treatments and cures. We have been doing this for more than 25 years and our work has resulted in a diagnostic for antibiotic resistance and four licensed medicines. This includes Keytruda®(cancer), Actemra® (rheumatoid arthritis), Tysabri® (multiple sclerosis) and Entyvio® (Crohn’s disease) and a test for antimicrobial resistance. Find out more about our work at www.lifearc.org or follow us on LinkedIn or Twitter (@lifearc1)
14
Total Investments
13
Portfolio Companies
-
Exits
-
Industries
General Information
Company Overview
Investment Criteria
Investment Thesis
•••••• •••••• ••••••
About LifeArc
Recent Investments (14)
View All| Company | Stage | Amount | Date |
|---|---|---|---|
| Series B | •••••• | May 2025 | |
| Series A | •••••• | Aug 2023 | |
| Series A | •••••• | Jul 2023 | |
| Series A | •••••• | Feb 2023 | |
| Seed Round | •••••• | Jan 2023 | |
|
|
Seed Round | •••••• | Nov 2022 |
|
|
Series A | •••••• | Dec 2021 |
|
|
Series A | •••••• | Nov 2021 |
|
|
Series B | •••••• | May 2021 |
|
|
Venture Round | •••••• | May 2021 |
All startup & investor data, one platform.
Filter investors by stage, sector, and geography. Compare portfolios side by side. Spot market signals before anyone else.